H.C. Wainwright raised the firm’s price target on Sangamo (SGMO) to $10 from $5 and keeps a Buy rating on the shares. The firm says the accelerated clinical development plan in Fabry disease may support an application filing in the first half of 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter